Print this page
-
AYA Cancer Survivor and Parent Communication and Transition Readiness
Protocol: 002308Applicable Disease Sites: Any Site
-
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies.
Protocol: 072014Applicable Disease Sites: Any Site
-
A Phase 2 Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer.
Protocol: 082203Principal Investigator:
-
Ryan Stephenson
Applicable Disease Sites: Kidney -
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma.
Protocol: 111406Principal Investigator:
-
Scott A Moerdler
Applicable Disease Sites: Any Site -
Project Every Child: A Registry, Eligibility Screening, Biology and Outcome Study.
Protocol: 111509Principal Investigator:
-
Richard A Drachtman
Applicable Disease Sites: Any Site -
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors.
Protocol: 111702Principal Investigator:
-
Archana Sharma
Applicable Disease Sites: Any Site
Ovary
Prostate -
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol.
Protocol: 111706Principal Investigator:
-
Richard A Drachtman
Applicable Disease Sites: Any Site -
A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL).
Protocol: 111707Principal Investigator:
-
Archana Sharma
Applicable Disease Sites: Lymphoid Leukemia -
Phase 1/2 Study to Evaluate Palbociclib (IBRANCE®) in Combination with Irinotecan and Temozolomide or in Combination with Topotecan and Cyclophosphamide in Pediatric Patients with Recurrent or Refractory Solid Tumors.
Protocol: 111901Principal Investigator:
-
Scott A Moerdler
Applicable Disease Sites: Any Site -
A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors.
Protocol: 111904Principal Investigator:
-
Scott A Moerdler
Applicable Disease Sites: Other Female Genital
Other Male Genital -
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL, Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy.
Protocol: 111911Principal Investigator:
-
Marissa Botwinick
Applicable Disease Sites: Any Site -
A Phase 3 Randomized Study of Selumetinib versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma.
Protocol: 111914Principal Investigator:
-
Scott A Moerdler
Applicable Disease Sites: Brain and Nervous System -
Concordance of Self-reported Race and Ethnicity with Hospital Records Among Pediatric Patients.
Protocol: 112001Principal Investigator:
-
Peter D. Cole
Applicable Disease Sites: Any Site -
Characterization of Brain Dysfunction During Development in Survivors of Childhood Acute Lymphoblastic Leukemia.
Protocol: 112002Principal Investigator:
-
Peter D. Cole
Applicable Disease Sites: Leukemia, not otherwise specified -
A Phase 2 Study of Blinatumomab in Combination with Nivolumab, a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged < 1 to < 31 Years Old with First Relapse.
Protocol: 112011Principal Investigator:
-
Richard A Drachtman
Applicable Disease Sites: Any Site -
A Phase 3 Study of Selumetinib or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations.
Protocol: 112102Principal Investigator:
-
Richard A Drachtman
Applicable Disease Sites: Brain and Nervous System